Capricor Therapeutics, Inc. (CAPR) financial statements (2020 and earlier)

Company profile

Business Address 8840 WILSHIRE BLVD
BEVERLY HILLS, CA 90211
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1076771012
Cash and cash equivalents4767446
Short-term investments6   366
Restricted cash and investments 000001
Receivables0000000
Other undisclosed current assets1000100
Total current assets:1177881114
Noncurrent Assets
Property, plant and equipment0011111
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Other undisclosed noncurrent assets0000000
Total noncurrent assets:1111111
TOTAL ASSETS:1187991214
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1121121
Other undisclosed accounts payable and accrued liabilities1121121
Other undisclosed current liabilities0000000
Total current liabilities:1122121
Noncurrent Liabilities
Other undisclosed noncurrent liabilities3333333
Total noncurrent liabilities:3333333
Total liabilities:4455555
Stockholders' equity
Stockholders' equity attributable to parent74245710
Common stock0000000
Additional paid in capital81767473717069
Accumulated other comprehensive income (loss)(0)   000
Accumulated deficit(74)(73)(71)(69)(67)(63)(59)
Total stockholders' equity:74245710
TOTAL LIABILITIES AND EQUITY:1187991214

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:0000100
Operating expenses(2)(2)(2)(3)(4)(4)(5)
Operating loss:(1)(2)(2)(3)(3)(4)(4)
Nonoperating income0000000
Investment income, nonoperating 000000
Net loss:(1)(2)(2)(3)(3)(4)(4)
Other undisclosed net income (loss) attributable to parent0 (0)    
Net loss available to common stockholders, diluted:(1)(2)(2)(3)(3)(4)(4)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(1)(2)(2)(3)(3)(4)(4)
Comprehensive loss:(1)(2)(2)(3)(3)(4)(4)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0 (0)(0)(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(1)(2)(2)(3)(3)(4)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: